期刊
NUCLEAR MEDICINE AND BIOLOGY
卷 38, 期 2, 页码 261-272出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2010.08.006
关键词
Radioligand development; Positron emission tomography (PET); Serotonin; 5-HT1B
资金
- AstraZeneca
- Swedish Science Council [VR 09114]
Introduction: The serotonin 1B (5-HT1B) receptor has been implicated in several psychiatric disorders and is a potential pharmacological target in the treatment of depression. The aim of this study was to develop a radioligand for positron emission tomography (PET) imaging of the 5-HT1B receptor in the primate brain in vivo. Methods: Eight carboxamide radioligands (1-8) from three different core structures were radiolabeled with carbon-11 employing N-methylation with [C-11]methyl triflate on the piperazine structural moiety. In vivo PET evaluation of each radioligand was performed in cynomolgus monkeys and included analysis of radioactive metabolites measured in plasma using high-performance liquid chromatography. Results: In a total of 12 radiosynthesis of the eight radioligands, the mean decay corrected yield was 11%, and the mean specific radioactivity was 299 CBq/mu mol (8075 Ci/mmol) at time of administration. Of the eight tested candidates, [C-11]6 demonstrated the most promising in vivo characteristics, showing high binding in 5-HT1B receptor-rich regions and low binding in the cerebellum. When inspecting data from all eight compounds, lipophilicity appeared as a physicochemical property that could be related to favorable in vivo imaging characteristics. Conclusion: Candidate [C-11]6, i.e., [C-11]AZ10419369, exhibited high binding potentials in regions known to contain 5-HT1B receptors and was nominated for further preclinical characterization and PET examination in human subjects. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据